Placeholder Banner

BIO Comments on REMS Assessment: Planning and Reporting

April 2, 2019

BIO submitted comments to the Food and Drug Administration (FDA) on the draft guidance, REMS Assessment: Planning and Reporting

BIO says the guidance offers clear, practical information to sponsors and other stakeholders involved in the design and effectiveness evaluation of REMS programs. It provides instrumental recommendations, particularly on how the REMS program goals, objectives, and design may impact the selection of metrics and data sources, which will be used to assess whether the program is meeting its risk mitigation goals.

BIO requests clarifications, particularly on how existing REMS would be grandfathered and evaluation of the burden on healthcare system and patient access. In addition, BIO would welcome the opportunity to partner with the FDA to define improved metrics to evaluate safety-related health outcomes. 

Download Full Comments Below
FINAL BIO Letter REMS Assessment Planning And Reporting
Read full comment letter below
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…